- Home
- NLSP vs OGEN Comparison
NLSP vs OGEN Comparison
Compare NLSP & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- OGEN
- Stock Information
- Founded
- NLSP 2015
- OGEN 1996
- Country
- NLSP Switzerland
- OGEN United States
- Employees
- NLSP N/A
- OGEN N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- NLSP Health Care
- OGEN Health Care
- Exchange
- NLSP Nasdaq
- OGEN Nasdaq
- Market Cap
- NLSP 12.4M
- OGEN 2.5M
- IPO Year
- NLSP 2021
- OGEN N/A
- Fundamental
- Price
- NLSP $2.24
- OGEN $1.40
- Analyst Decision
- NLSP
- OGEN
- Analyst Count
- NLSP 0
- OGEN 0
- Target Price
- NLSP N/A
- OGEN N/A
- AVG Volume (30 Days)
- NLSP 308.9K
- OGEN 1.3M
- Earning Date
- NLSP 07-29-2025
- OGEN 08-08-2025
- Dividend Yield
- NLSP N/A
- OGEN N/A
- EPS Growth
- NLSP N/A
- OGEN N/A
- EPS
- NLSP N/A
- OGEN N/A
- Revenue
- NLSP N/A
- OGEN N/A
- Revenue This Year
- NLSP N/A
- OGEN N/A
- Revenue Next Year
- NLSP N/A
- OGEN N/A
- P/E Ratio
- NLSP N/A
- OGEN N/A
- Revenue Growth
- NLSP N/A
- OGEN N/A
- 52 Week Low
- NLSP $1.30
- OGEN $1.30
- 52 Week High
- NLSP $15.59
- OGEN $75.60
- Technical
- Relative Strength Index (RSI)
- NLSP 46.57
- OGEN 28.42
- Support Level
- NLSP $2.06
- OGEN $1.30
- Resistance Level
- NLSP $2.35
- OGEN $1.58
- Average True Range (ATR)
- NLSP 0.22
- OGEN 0.15
- MACD
- NLSP -0.04
- OGEN 0.02
- Stochastic Oscillator
- NLSP 14.33
- OGEN 4.07
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.